177 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
17 Jun 24
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
8:03am
. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
14 Jun 24
Condensed Consolidated Financial Statements
4:30pm
Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
3 Jun 24
Report of Foreign Private Issuer
8:05am
harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks
6-K
EX-1.1
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.
(j) Litigation … or Ordinary Share Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.
4.8 Indemnification
424B5
qv13oxg
29 May 24
Prospectus supplement for primary offering
4:15pm
6-K
EX-99.1
6spo4jhu55bexdre
28 May 24
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
8:13am
6-K
EX-99.1
fprzt xt5
29 Apr 24
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
8:01am
6-K
EX-99.1
pbholebe4b8p nkib
22 Apr 24
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
9jxiv0go5p 2l4
16 Apr 24
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
lgn329ggbj3zt v3i619
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
6-K
EX-99.1
h0me57r ybkw
29 Mar 24
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
dnjbqrqp
7 Feb 24
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
8:02am
6-K
e9jh9 e7in01
22 Jan 24
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
xgc4f4f0 mwnkfztm
17 Jan 24
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
nez6dtmh
20 Dec 23
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
8:01am
6-K
EX-99.2
7pjj0mx1bs9d03fugfe
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
6-K
d2n5b11
7 Nov 23
Report of Foreign Private Issuer
4:30pm